Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.
Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.
复制标题
使用新型CD160-ROR1分析，高度敏感，准确地评估了慢性淋巴细胞性白血病中最小残留疾病。
DOI：
10.3389/fonc.2020.597730
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
Agrawal SG
中科院分区：
文献类型：
--
作者：
Farren TW;Sadanand KS;Agrawal SG
慢性淋巴细胞白血病（CLL）中不可检测的微小残留病（MRD）与可检测的MRD相比具有良好的预后结果。本研究研究了一种靶向肿瘤特异性抗原CD 160和受体酪氨酸激酶样孤儿受体1（ROR 1）沿着CD 2、CD 5、CD 19、CD 45的流式细胞术测定（CD 160-ROR 1FCA）。将CD 160-ROR 1FCA与最初发表的8色欧洲CLL研究倡议（ERIC）金标准检测CLL MRD进行比较。CD 160-ROR 1FCA的检测限为0.001%，并显示与ERIC的强相关性（R = 0.98，p < 0.01），MRD检测的差异可忽略不计（偏倚-0.3152 95%CI 5.586至-6.216）。使用CD 160-ROR 1 FCA，与低水平多克隆B细胞扩增相比，在单克隆B细胞淋巴细胞增多症（MBL）中发现CD 160和ROR 1的表达增加（p < 0.01）。CR和未检测到MRD的患者的EFS（未达到）长于CR但可检测到MRD的患者（756天，p < 0.01），而部分缓解患者为113天（p < 0.01）。MRD水平>0.01至0.1%的患者的EFS较长（2，333天），而水平在0.1至1%之间（1，049天）。CD 160-ROR 1FCA是一种用于常规CLL MRD测量和MBL检测的新型检测方法。CLL治疗后通过CD 160-ROR 1FCA评估的MRD状态与EFS相关。
Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like orphan receptor 1 (ROR1), along with CD2, CD5, CD19, CD45. CD160-ROR1FCA was compared with the originally published 8-colour European Research Initiative for CLL (ERIC) gold-standard assay for CLL MRD detection. CD160-ROR1FCA had a limit of detection of 0.001% and showed strong correlation with ERIC (R = 0.98, p < 0.01) with negligible differences in MRD detection (bias -0.3152 95%CI 5.586 to -6.216). Using CD160-ROR1FCA, increased expression of both CD160 and ROR1 was found in Monoclonal B cell Lymphocytosis (MBL) compared to low-level polyclonal B-cell expansions (p < 0.01). Patients in CR and with undetectable MRD had a longer EFS (not reached) than those in CR but with detectable MRD (756 days, p < 0.01) versus 113 days in patients with partial remission (p < 0.01). Patients with MRD levels of >0.01 to 0.1% had a longer EFS (2,333 days), versus levels between 0.1 to 1% (1,049 days). CD160-ROR1FCA is a novel assay for routine CLL MRD measurement and for MBL detection. MRD status assessed by CD160-ROR1FCA after CLL treatment correlated with EFS.
登录
查看更多内容
影响因子：
20.3
作者：
Liu, Feng-Ting;Giustiniani, Jerome;Agrawal, Samir G.
通讯作者：
Agrawal, Samir G.
影响因子：
6.5
作者：
Choudhury, Aniruddha;Derkow, Katja;Mellstedt, Hakan
通讯作者：
Mellstedt, Hakan
影响因子：
11.4
作者：
Daneshmanesh, A. H.;Hojjat-Farsangi, M.;Mellstedt, H.
通讯作者：
Mellstedt, H.
影响因子：
1.3
作者：
Dowling, Anita K.;Liptrot, Stuart D.;Vandenberghe, Elisabeth
通讯作者：
Vandenberghe, Elisabeth
DOI：
10.1073/pnas.0712148105
发表时间：
2008-02-26
影响因子：
11.1
作者：
Fukuda, Tetsuya;Chen, Liguang;Kipps, Thomas J.
通讯作者：
Kipps, Thomas J.